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  By  segregating  individual  target  DNA  molecules  into  millions  of  aqueous 
droplets  acting  as  independent  microreactors,  our  procedure  allows  for  extremely 
precise,  sensitive,  and  fast  quantification  of  mutated  genes.  The  sensitivity  of  the 
procedure was confirmed by measuring 1/200,000 dilution of KRAS-mutated cell-line 
DNA in a background of wild-type DNA. Furthermore, plasma of more than 50 patients 
with  metastatic  CRC  were  tested.  Our  procedure  enabled  detection  of  the  target 
mutation and the wild-type DNA, and thus, measurement of the total amplifiable DNA. 
DNA concentration in the plasma samples varied by two orders of magnitude and was 
not correlated with the proportion of mutated DNA, which varied from 42% to 0.1%. By 
using a duplex analysis to detect either of the two most frequent mutations of KRAS 
(G12D and G13D) and the wild-type DNA, the expected mutation (known by primary 
tumor characterization) was detected in 16 out of the 19 samples. Two samples had a 
low  amount  of  amplifiable  DNA  leading  to  an  inconclusive  result.  Five  samples, 
positive for the G13D mutation, were also tested for the G12D mutations and were 
negative.  Moreover,  we  tested  54  plasma  samples  from  patients  with  metastatic 
cancer with known KRAS status (mutated or not) in a multiplex format allowing the 
simultaneous analysis of the seven more frequent mutations of KRAS or the wild-type 
sequence. Among the mutated samples, 13 out the 19 mutated ones were positive and 
32 of the non mutated ones were negatives.  
 Our results demonstrate that our digital PCR method enables non-invasive 
detection of KRAS in plasma of patients with metastatic CRC with high sensitivity and 
high specificity. We anticipate that the method will be employed in multiple applications 
in  the  clinic,  including  diagnosis,  cancer  recurrence  monitoring,  and  treatment 
management. 
  Circulating  tumor  DNA  (ctDNA)  is  present  in  plasma  of  individuals  with 
advanced cancers.1 ctDNA is a prognostic marker for patients with colorectal cancer 
(CRC) and it might also be used for predicting the response to targeted therapy. For 
example, mutations in KRAS indicate which patients will fail to respond to specific 
therapies (cetuximab, panitunimab).2 Although ctDNA is characterized by the presence 
of a somatic mutation, direct quantitative detection through a simple workflow of such 
mutant DNA is not feasible by current technologies because the ratio of ctDNA to wild-
type DNA can be as low as 1/10,000.  
 This study describes the use of droplet-based digital PCR for detection and 
quantitation of one of the seven most frequent KRAS mutations in ctDNA from plasma 
of  patients  with  advanced  colorectal  cancer.  Furthermore,  we  demonstrate  that 
multiplex digital PCR enables testing samples for different mutations simultaneously. 
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Figure 1: Droplet-based PCR approach3,4.  
a. Patient sample containing low level of mutant sequences in a high background of 
wild-type sequences. 
b. Sample diluted to single molecule per droplet and partitioned into millions of 
reaction droplets. 
c. End point PCR produces positive and negative reactions. 
d. Droplets flow past laser; two color fluorescent detection yields positive (wild type 
and mutant) and negative (dark) droplets. 
Figure  4:  TaqMan  assays  for  each  of  the  seven  most 
frequent  mutations  of  KRAS  were  assembled  into  two 
multiplex  panels  by  mixing  mutation-specific  VIC  and/or 
FAM TaqMan probes with a single wild-type (VIC) probe 
and a single pair of PCR primers in each panel. The heat-
map histograms reveal that concentrations of probes were 
tuned  to  enable  discrimination  of  droplets  containing  no 
amplifiable  fragments,  wild-type  KRAS  DNA,  or  a  DNA 
fragment with a unique KRAS mutation. 
Quantitative detection of circulating tumor 
DNA  
Figure 2: An aqueous phase containing the gDNA, PCR reagents and TaqMan® probes specific for the wild-
type and mutant genes is emulsified within a microfluidic device. The emulsion is collected and thermocycled. 
During DNA amplification, the TaqMan® probes are cleaved and the corresponding fluorophores are released. 
The TaqMan® probes recognizing wild-type alleles carried a red-fluorescent fluorophore and TaqMan® probes 
specific for the mutant sequences carried a green fluorophore. 
Figure 3: Sensitivity of the method. Serial dilutions of mutant KRAS DNA were 
prepared by adding wild-type KRAS DNA over five decades of concentration to 
demonstrate  the  sensitivity  of  the  digital  PCR  method.  The  figure  reveals 
detection of the mutant at a level of 1:200,000 in wild-type KRAS within the 95% 
confidence intervals (represented by the orange shading). 
A highly sensitive and quantitative procedure. To demonstrate that genes bearing a somatic mutation can 
be detected within a large excess of wild type sequences, gDNA from a heterozygous cell-line bearing a KRAS 
mutation, was serially diluted into gDNA containing the wild-type KRAS gene. By analyzing 106 fluorescent 
droplets, even the results obtained for the highest dilution (1/200,000) fall within the 95% confidence interval3. 
As a comparison, when using the same probes and same cell-lines, we previously demonstrated a sensitivity of 
10%.2 The method is thus, both sensitive and quantitative, the sensitivity being limited only by the number of 
droplets analyzed. 
Taqman reaction in droplets. As a proof of principle, gDNA extracted from different cell-lines was tested. The 
amplification of mutant DNA gives green-fluorescent droplets while the amplification of wild-type DNA gives red-
fluorescent droplets3. The emulsion is then reinjected onto a microfluidic chip, the droplets are spaced by oil, 
and the fluorescent signal of each droplet is analyzed. Droplets can also be analyzed with confocal microscopy 
Unprecedented Multiplexing Capability With Droplet-Based dPCR 
Multiplexing enables development of assays for biomarker panels at reduced cost and sample consumption, 
increased throughput and the potential for built-in assay controls. Conventional qPCR has limited multiplexing 
capability due to spectral overlap of fluorescent probes. A new method for differentiating targets on the basis of 
fluorescence intensity was developed by varying the concentration of the fluorescent probes4. To demonstrate, 
results  of  a  4-  and  5-plex  TaqMan®  dPCR  copy  number  assay  for  KRAS  mutations  were  measured 
simultaneously with just VIC and FAM fluorophores. This approach can be expanded to higher plex levels. 
Figure 5: DNA isolated from one of seven tumor 
cell-lines was mixed with wild-type DNA to prepare 
serial dilutions over four decades of mutant-to-wild-
type ratio.  Each of the samples were analyzed with 
the appropriate multiplex digital PCR panel.   The 
results  indicate  that  each  mutation  is  detectable 
across the range of concentrations. 
Detection  of  KRAS  G12D  mutation  in  DNA  isolated  from  plasma-  comparison  between  duplex  and 
multiplex procedures. 
Figure 6: DNA was isolated from plasma of a patient with metastatic colorectal cancer.  The DNA sample was 
split and analyzed by a duplex digital PCR assay and a multiplex digital PCR assay both both the presence of 
the  G12D  (the  mutation  that  have  been  highlighted  previously  in  the  corresponding  tumor)  and  wild-type 
sequences. The results from the two analyses are the same.  In both cases – duplex or multiplex – digital PCR 
reveals that approximately 0.5% of the circulating KRAS DNA is the G12D mutation. 
Duplex  detection.  The  analysis  of 
~700 ng DNA isolated from plasma of 
patient  with  metastatic  colorectal 
cancer  revealed    0.58%  of  G12D 
mutant  alleles  in  wild-type 
sequences. 
Multiplex  detection.  The 
analysis of ~550 ng DNA isolated 
from  plasma  of  patient  with 
metastatic  colorectal  cancer 
revealed 0.54% of G12D mutant 
alleles in wild-type sequences. 
Cell-free circulating DNA isolated from plasma of 19 
patients  with  metastatic  colon  cancer  was  analyzed 
with one or more duplex digital PCR assay. Tumors 
of these patients have been previously characterized 
for their mutational status.  
- 16 plasma samples matched the mutation identified in 
the tumor 
-  2 were negative for the expected mutation.  
-  1 sample was inconclusive.  
Circulating DNAs isolated from plasma of 54 patients 
with  metastatic  colon  cancer  were  analyzed  with  two 
multiplex digital PCR assays to detect the seven most 
common KRAS mutations. 
- 19 samples were expected to be positive for a KRAS 
mutation  based  on  previous  tumor  DNA 
characterization. 
-   13  samples  matched  the  mutation  identified  in  the 
tumor DNA. 
- 1 plasma sample contained a mutation different from 
the one expected from the tumor characterization (***). 
-   No  mutation  was  detected  in  1  plasma  sample  for 
which a mutation was expected. 
-    4  samples  were  inconclusive  for  the  expected 
mutation (2 were positive in duplex analysis). 
-  2 plasma samples were positive for a mutation but no 
mutation was detected in the tumors. For one of these 
samples(*), the initial tumor sample contained less than 
15% of tumor cells and interestingly the patient had a 
progressive  disease  at  the  first  evaluation  under 
cetuximab.  The  other  (**)  was  not  evaluated  for  the 
number of tumor cells due to the size of the biopsy.  
Figure  8:  Proportion  of  mutated  DNA 
observed  in  the  plasma  samples  tested  with 
multiplex droplet-based digital PCR for the 
different targeted mutations. 
Sensitivity detection of KRAS alleles in the multiplex procedure. 
Figure 7: Proportion of mutated DNA observed 
in  the  plasma  samples  tested  with  duplex 
droplet-based  digital  PCR  for  the  different 
targeted mutations. 
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Performing multiplex reactions in droplets  
Droplet-based digital PCR is used to detect and quantify the seven most frequent KRAS mutations in circulating tumor DNA of patients with advanced colorectal cancer.  
 -  The  droplet-based digital PCR method is versatile and two modes of analysis are demonstrated:  
      o   Duplex analysis enables sensitive detection of wild-type DNA plus one KRAS or BRAF mutation. 
      o   Multiplex analysis enables simultaneous detection of wild-type DNA plus 3 or 4 KRAS mutations. 
 -  Detection of rare sequences is highly sensitive compared to the same Taqman assay in bulk (10% LLOD bulk vs 0.0005% LLOD droplets). 
 -  Biomarkers detection is quantitative: the fraction of mutated DNA in patient samples ranges from 0.1% to 42%. 
 -  Results from circulating tumor DNA analysis match the tumor DNA characterization in most cases, and discordant results reveal need for further studies. 